Loading…
Loading…
LVTX (LAVA Therapeutics N.V.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
LVTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LVTX and 80,000+ other tickers.
See exactly how LVTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LVTX and 80,000+ other tickers.
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for…
LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has received an average rating of "Reduce" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 1 year price
LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has been assigned a consensus rating of "Reduce" from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12 month target
Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA's common shares, representing approximately 87% of LAVA's outstanding common shares, were validly tendered and not withdrawn prior to the expiration of the initial offering period one minute after 11:59 p.m.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation (“XOMA”) (NASDAQ: XOMA).